|Day Low/High||98.45 / 99.33|
|52 Wk Low/High||58.59 / 99.36|
It seemed just a matter of time before M&A returned to the biotech industry with a vengeance.
Jim discusses Thursday's market selloff, what Apple's preannouncement means for the stock long term, the announced Bristol-Myers Squibb acquisition of Celgene and how it relates to Amgen, the oil market, and much more!
Jim Cramer's thoughts on Bristol-Myers and how it sets the stage for mergers and acquisitions going into 2019.
Big pharma could be primed for an M&A Boom after Bristol-Myers Squibb's blockbuster deal for Celgene.
BMY agreed to acquire CELG for $74 billion in cash and stock.
Jim Cramer's thoughts on the Bristol-Myers deal and Apple's issues with China.
The big problem this market faces technically is that there isn't much support down to the lows hit on Dec. 24.
Jim Cramer's back and ready to tackle the Bristol-Myers Celgene deal, Apple and the markets.
Bristol-Myers Squibb Company (NYSE:BMY) and Celgene Corporation (NASDAQ:CELG) today announced that they have entered into a definitive merger agreement under which Bristol-Myers Squibb will acquire Celgene in a cash and stock transaction with an equity...
The market's day-to-day extreme volatility tested even the most seasoned investors. Adhering to portfolio principles can help.
Celgene Corporation (NASDAQ:CELG) will present a business update and provide 2019 financial guidance at the 37 th Annual J.
Celgene Corporation (NASDAQ:CELG) today announced ten programs selected for funding under its Celgene Cancer Care Links™ program, an initiative designed to support cancer healthcare capacity building in resource-constrained countries around the world.
It can be disturbing to see various names lose value quickly on no news, but here is a method to take advantage of such moves.
Celgene Corporation (NASDAQ:CELG) today announced initial safety data from its ongoing proof-of-concept trial of JCARH125 in patients with relapsed/refractory multiple myeloma.
Celgene Corporation (NASDAQ: CELG) today announced results of the phase 3 AUGMENT study, which showed that REVLIMID ® (lenalidomide) in combination with rituximab (R 2) demonstrated superior progression-free survival (PFS) in patients with...
bluebird bio, Inc. (Nasdaq:BLUE) and Celgene Corporation (NASDAQ:CELG) announced initial data from the ongoing Phase 1 clinical study of bb21217 (CRB-402), an investigational next-generation anti-BCMA CAR T cell therapy being studied in patients with...
Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced results from the pivotal, phase 3 MEDALIST trial evaluating the efficacy and safety of investigational luspatercept to treat patients with ring sideroblast (RS+)...
Celgene Corporation (NASDAQ: CELG) today announced initial data from the dose-escalation part of an ongoing, open-label multicenter phase 1/2 study of investigational lisocabtagene maraleucel (liso-cel; JCAR017) in patients with relapsed/refractory...
Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced results from a pivotal, phase 3 trial (BELIEVE) evaluating the safety and efficacy of luspatercept for the treatment of adults with beta-thalassemia-associated...
Both names looked poised to go higher as soon as sentiment around the small biotech sector improves.
Celgene could be at a temporary low or it could be starting a new base pattern.
Celgene Corporation (Nasdaq: CELG) and bluebird bio, Inc. (Nasdaq: BLUE) today announced the completion of enrollment for the KarMMa pivotal study of bb2121, the companies' lead investigational anti-BCMA CAR T cell therapy candidate for patients with...
What comes next? Anything concrete to justify this rally? Sorry, says Jim Cramer. It's just a reprieve, not a sustainable turnaround.
I tire of hearing that there has been a correction.
Biotech ETFs could mitigate risk amid the sector's volatility, and names such as Exelixis, ANI Pharmaceuticals and Progenics hold promise.
I continue to deploy 'dry powder' into the biotech sector on dips using Buy-Write option strategies.
Jim Cramer explains his post-election play book: Growth stocks may be the way to go.
Jim Cramer weighs in on Canada Goose, Celgene, BlackRock, Nio, Hospitality Property Trust, Activision Blizzard and more.
Eli Lilly's confirmation of acquisition action could make pharmaceuticals an attractive investment space.
Celgene Corporation (NASDAQ:CELG) plans to present at two upcoming investor events where Celgene management will provide an overview of the Company.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.